Riesgo de acidosis láctica fatal y no fatal con el uso de metformina para la diabetes mellitus tipo 2
Characteristics of included studies Notes Allocation concealment
D
Study
Lean 1983
Methods
TRIAL DESIGN: Prospective cohort study or metformin in a randomised controlled trial of ciclazindol DURATION: 2 months
Participants
COUNTRY: United Kingdom SETTING: outpatient Treatment N: 10 Control N: 0 AGE: 42-68 SEX: 30% men INCLUSION: obese patients with type 2 DM, treated with metformin EXCLUSIONS: hepatic or renal impairment, heart disease, psychiatric or alcohol problems
Interventions
TREATMENT: metformin 500 mg BID + placebo or metformin + ciclazindol 25-75 mg/day COMPARISON: none
Outcomes
Plasma insulin, triglycerides, lactate pyruvate, and weight.
Notes Allocation concealment
D
Study
Lee 1998
Methods
TRIAL DESIGN: Double-blind randomised controlled trial DURATION: 24 weeks
Participants
COUNTRY: United States SETTING: University center Treatment N: 24 Control N: 120 Treatment AGE: 59+/-3 Control AGE: 61+/-2 SEX: 0 men INCLUSION: Obese type 2 DM EXCLUSIONS: major illnes, cardiac, renal or hepatic disorder, medicine known to affect body weight or cholesterol metabolism
Interventions
TREATMENT: Metformin 850 mg BID COMPARISON: placebo
Outcomes
Food consumption and weight loss
Notes Allocation concealment
B
Study
Lord 1983
Methods
TRIAL DESIGN: Open-label cross-over trial with untreated controls DURATION: 4 weeks
Página 69
Copyright © John Wiley & Sons Ltd. Usado con permiso de John Wiley & Sons, Ltd.